| Budget Amount *help |
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2016: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
Siglecs expressed in various immune cells recognize sialic acids and mostly inhibit cell activation. In this study, we demonstrated that sialic acid-containing Siglec ligands expressed on the same cell (cis-ligands) can be efficiently labeled by proximity labeling. We elucidated how cis-ligands regulate Siglecs by analyzing CD45 that was isolated as a cis-ligand of CD22, a Siglec. Moreover, we demonstrated that the polymorphism of Siglec-10 associated with Guillain-Barre syndrome in which autoantibodies to gangliosides, sialic acid-containing glycolipids, are produced regulates binding of Siglec-10 to gangliosides. This result suggests that decreased activity of Siglec-10 allows immune responses to gangliosides, resulting in development of this syndrome.
|
